<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00910208</url>
  </required_header>
  <id_info>
    <org_study_id>2008-448</org_study_id>
    <secondary_id>1R21NR010929-01</secondary_id>
    <nct_id>NCT00910208</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Patient Controlled Analgesia in the Emergency Department</brief_title>
  <official_title>Safety and Efficacy of Patient Controlled Analgesia in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jacobi Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to assess efficacy and safety of patient-controlled analgesia
      (PCA) when applied to the Emergency Department setting and to compare the efficacy and safety
      of two PCA dosing regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The safety, efficacy, and dosing of PCA will be assessed in a randomized trial with three
      treatment arms:

        1. PCA with 1.0 mg morphine demand dosing every 6 minutes,

        2. PCA with 1.5 mg demand dosing every 6 minutes and

        3. a non-PCA comparison group.

      All patients will receive a loading dose of 0.1 mg/kg morphine. All patients can receive
      additional analgesics as needed, at the discretion of the provider.

      We hypothesize that morphine supplied via PCA will provide superior analgesia without a
      greater incidence of adverse events when compared to non-PCA pain management; and that PCA
      demand dosing of 1.5 mg will be superior to 1.0 mg without more adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short Term Efficacy: Change in Pain Intensity as Assessed by Patient Self Report on Numerical Rating Scale</measure>
    <time_frame>Baseline and 30 minutes post treatment</time_frame>
    <description>Participants will complete a survey in which they rate their pain on a Numerical Rating Scale (NRS) of pain ranging from 0 - no pain, to 10 - worst imaginable pain, higher scores indicate worse pain. Change is measured by subtracting the 30 minute NRS score from the Baseline NRS score, thus higher numbers indicate greater decrease in pain, negative numbers indicate increase in pain from baseline to 30 minutes post-baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Short Term Efficacy: Pain Relief by 30 Minutes</measure>
    <time_frame>30 minutes post treatment</time_frame>
    <description>Pain Intensity measured on Likert Scale. Participants self report pain level according to the scale by selecting from No relief, Slight relief, Moderate relief, A lot of relief, and Complete relief)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long Term Efficacy: Total Analgesia Provided Over 2 Hours</measure>
    <time_frame>Baseline, 30, 60, 90, 120 post-treatment</time_frame>
    <description>Participants will complete a survey in which they rate their pain on a Numerical Rating Scale (NRS) of pain ranging from 0 - no pain, to 10 - worst imaginable pain, higher scores indicate worse pain
Total analgesia is measured by a summary of change in pain that varies from 0 - no change to</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long Term Efficacy: Pain Relief by 120 Minutes</measure>
    <time_frame>120 minutes</time_frame>
    <description>Participants aksed to and give range</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence of Adverse Events</measure>
    <time_frame>2 hours</time_frame>
    <description>Adverse Events defined as: oxygen saturation &lt; 92%; respiratory rate &lt;10 breaths/min; systolic blood pressure &lt; 90 mm Hg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for Supplementary Analgesia</measure>
    <time_frame>2 hours post treatment</time_frame>
    <description>count of participants who needed or did not needed additional analgesia</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Patient-controlled analgesia 1 mg demand dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mg/kg morphine loading dose plus PCA with 1.0 mg morphine demand dosing every 6 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient-controlled analgesia 1.5 mg demand dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mg/kg morphine loading dose plus PCA with 1.5 mg morphine demand dosing every 6 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Patient-controlled analgesia comparison group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 mg/kg morphine loading dose plus additional analgesia as needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patient-controlled analgesia</intervention_name>
    <description>Intravenous morphine delivered via Curlin painsmart PCA device</description>
    <arm_group_label>Patient-controlled analgesia 1 mg demand dose</arm_group_label>
    <arm_group_label>Patient-controlled analgesia 1.5 mg demand dose</arm_group_label>
    <other_name>PCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>morphine</intervention_name>
    <description>Intravenous morphine</description>
    <arm_group_label>Non-Patient-controlled analgesia comparison group</arm_group_label>
    <arm_group_label>Patient-controlled analgesia 1 mg demand dose</arm_group_label>
    <arm_group_label>Patient-controlled analgesia 1.5 mg demand dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting to the ED with a chief complaint of abdominal pain of less than or
             equal to 7 days duration

          -  Age 18 to 65 years

          -  Patient deemed by the ED attending physician to require IV opioid analgesia

        Exclusion Criteria:

          -  Current use of prescription or non-prescription opioids

          -  Long-term use of opioids, chronic pain syndrome

          -  Clinician suspicion of opioid dependence/abuse

          -  Clinical suspicion of intoxication

          -  Pregnancy or breast-feeding

          -  History of chronic obstructive pulmonary disease, history of sleep apnea, oxygen
             saturation &lt; 97%

          -  Systolic blood pressure &lt; 100 mm Hg

          -  Use of monoamine oxidase inhibitors, phenothiazines, or tricyclic antidepressants

          -  History of renal insufficiency/renal failure

          -  Prior allergic reaction to morphine

          -  Inability to provide informed consent

          -  Previous entry of patient into study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrienne J Birnbaum, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jacobi Medical Center, Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Polly E Bijur, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 27, 2009</study_first_submitted>
  <study_first_submitted_qc>May 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2009</study_first_posted>
  <results_first_submitted>November 1, 2018</results_first_submitted>
  <results_first_submitted_qc>December 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 27, 2019</results_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Analgesia, Patient-controlled</keyword>
  <keyword>Emergency Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started April 3, 2009 and ended June 30, 2010. Patients were recruited by bilingual research associates in the Emergency Department of Jacobi Medical Center, Bronx, NY</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PCA 1 mg Demand Dose</title>
          <description>0.1 mg/kg morphine loading dose followed by PCA with 1.0 mg morphine demand dose every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
        </group>
        <group group_id="P2">
          <title>PCA 1.5 mg Demand Dose</title>
          <description>0.1 mg/kg morphine loading dose followed by PCA with 1.5 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
        </group>
        <group group_id="P3">
          <title>Non-PCA Comparison Group</title>
          <description>0.1 mg/kg morphine loading dose followed by additional analgesia supplemented as needed at the discretion of the treating physician, using usual procedures for monitoring and treating pain.
morphine: Intravenous morphine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PCA 1 mg Demand Dose</title>
          <description>0.1 mg/kg morphine loading dose followed by PCA with 1.0 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
        </group>
        <group group_id="B2">
          <title>PCA 1.5 mg Demand Dose</title>
          <description>0.1 mg/kg morphine loading dose followed by PCA with 1.5 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
        </group>
        <group group_id="B3">
          <title>Non-PCA Comparison Group</title>
          <description>0.1 mg/kg morphine loading dose followed by additional analgesia supplemented as needed at the discretion of the treating physician, using usual procedures for monitoring and treating pain.
morphine: Intravenous morphine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="206"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="10"/>
                    <measurement group_id="B2" value="38" spread="12"/>
                    <measurement group_id="B3" value="37" spread="12"/>
                    <measurement group_id="B4" value="36" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race and ethnicity were asked separately. As the majority of patients who identified their ethnicity as Hispanic/Latino did not specify a race, patients were categorized as Hispanic/Latino regardless of race. If patients were not Hispanic/Latino, they were categorized by race</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American - not Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - not Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial Pain Score</title>
          <description>Numerical rating scale (NRS) of pain: 0 indicates no pain, 10 indicates worst possible pain</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Pain Score less than 7</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pain Score=7</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pain Score=8</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pain Score=9</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pain Score=10</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Short Term Efficacy: Change in Pain Intensity as Assessed by Patient Self Report on Numerical Rating Scale</title>
        <description>Participants will complete a survey in which they rate their pain on a Numerical Rating Scale (NRS) of pain ranging from 0 - no pain, to 10 - worst imaginable pain, higher scores indicate worse pain. Change is measured by subtracting the 30 minute NRS score from the Baseline NRS score, thus higher numbers indicate greater decrease in pain, negative numbers indicate increase in pain from baseline to 30 minutes post-baseline.</description>
        <time_frame>Baseline and 30 minutes post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCA 1 mg Demand Dose</title>
            <description>0.1 mg/kg morphine loading dose followed by PCA with 1.0 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
          </group>
          <group group_id="O2">
            <title>PCA 1.5 mg Demand Dose</title>
            <description>0.1 mg/kg morphine loading dose followed by PCA with 1.5 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
          </group>
          <group group_id="O3">
            <title>Non-PCA Comparison Group</title>
            <description>0.1 mg/kg morphine loading dose followed by additional analgesia supplemented as needed at the discretion of the treating physician, using usual procedures for monitoring and treating pain.
morphine: Intravenous morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Short Term Efficacy: Change in Pain Intensity as Assessed by Patient Self Report on Numerical Rating Scale</title>
          <description>Participants will complete a survey in which they rate their pain on a Numerical Rating Scale (NRS) of pain ranging from 0 - no pain, to 10 - worst imaginable pain, higher scores indicate worse pain. Change is measured by subtracting the 30 minute NRS score from the Baseline NRS score, thus higher numbers indicate greater decrease in pain, negative numbers indicate increase in pain from baseline to 30 minutes post-baseline.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="3.0" upper_limit="4.6"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.3" upper_limit="4.6"/>
                    <measurement group_id="O3" value="3.6" lower_limit="2.9" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Short Term Efficacy: Pain Relief by 30 Minutes</title>
        <description>Pain Intensity measured on Likert Scale. Participants self report pain level according to the scale by selecting from No relief, Slight relief, Moderate relief, A lot of relief, and Complete relief)</description>
        <time_frame>30 minutes post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCA 1 mg Demand Dose</title>
            <description>0.1 mg/kg morphine loading dose followed by PCA with 1.0 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
          </group>
          <group group_id="O2">
            <title>PCA 1.5 mg Demand Dose</title>
            <description>0.1 mg/kg morphine loading dose followed by PCA with 1.5 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
          </group>
          <group group_id="O3">
            <title>Non-PCA Comparison Group</title>
            <description>0.1 mg/kg morphine loading dose followed by additional analgesia supplemented as needed at the discretion of the treating physician, using usual procedures for monitoring and treating pain.
morphine: Intravenous morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Short Term Efficacy: Pain Relief by 30 Minutes</title>
          <description>Pain Intensity measured on Likert Scale. Participants self report pain level according to the scale by selecting from No relief, Slight relief, Moderate relief, A lot of relief, and Complete relief)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A lot of relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long Term Efficacy: Total Analgesia Provided Over 2 Hours</title>
        <description>Participants will complete a survey in which they rate their pain on a Numerical Rating Scale (NRS) of pain ranging from 0 - no pain, to 10 - worst imaginable pain, higher scores indicate worse pain
Total analgesia is measured by a summary of change in pain that varies from 0 - no change to</description>
        <time_frame>Baseline, 30, 60, 90, 120 post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCA 1 mg Demand Dose</title>
            <description>0.1 mg/kg morphine loading dose followed by PCA with 1.0 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
          </group>
          <group group_id="O2">
            <title>PCA 1.5 mg Demand Dose</title>
            <description>0.1 mg/kg morphine loading dose followed by PCA with 1.5 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
          </group>
          <group group_id="O3">
            <title>Non-PCA Comparison Group</title>
            <description>0.1 mg/kg morphine loading dose followed by additional analgesia supplemented as needed at the discretion of the treating physician, using usual procedures for monitoring and treating pain.
morphine: Intravenous morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Long Term Efficacy: Total Analgesia Provided Over 2 Hours</title>
          <description>Participants will complete a survey in which they rate their pain on a Numerical Rating Scale (NRS) of pain ranging from 0 - no pain, to 10 - worst imaginable pain, higher scores indicate worse pain
Total analgesia is measured by a summary of change in pain that varies from 0 - no change to</description>
          <units>scores on a scale *minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" lower_limit="-18.8" upper_limit="-14.1"/>
                    <measurement group_id="O2" value="-17.4" lower_limit="-19.7" upper_limit="-15.1"/>
                    <measurement group_id="O3" value="-13.6" lower_limit="-15.9" upper_limit="-11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long Term Efficacy: Pain Relief by 120 Minutes</title>
        <description>Participants aksed to and give range</description>
        <time_frame>120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCA 1 mg Demand Dose</title>
            <description>0.1 mg/kg morphine loading dose followed by PCA with 1.0 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
          </group>
          <group group_id="O2">
            <title>PCA 1.5 mg Demand Dose</title>
            <description>0.1 mg/kg morphine loading dose followed by PCA with 1.5 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
          </group>
          <group group_id="O3">
            <title>Non-PCA Comparison Group</title>
            <description>0.1 mg/kg morphine loading dose followed by additional analgesia supplemented as needed at the discretion of the treating physician, using usual procedures for monitoring and treating pain.
morphine: Intravenous morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Long Term Efficacy: Pain Relief by 120 Minutes</title>
          <description>Participants aksed to and give range</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A lot of relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Incidence of Adverse Events</title>
        <description>Adverse Events defined as: oxygen saturation &lt; 92%; respiratory rate &lt;10 breaths/min; systolic blood pressure &lt; 90 mm Hg)</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCA 1 mg Demand Dose</title>
            <description>0.1 mg/kg morphine loading dose followed by PCA with 1.0 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
          </group>
          <group group_id="O2">
            <title>PCA 1.5 mg Demand Dose</title>
            <description>0.1 mg/kg morphine loading dose followed by PCA with 1.5 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
          </group>
          <group group_id="O3">
            <title>Non-PCA Comparison Group</title>
            <description>0.1 mg/kg morphine loading dose followed by additional analgesia supplemented as needed at the discretion of the treating physician, using usual procedures for monitoring and treating pain.
morphine: Intravenous morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Incidence of Adverse Events</title>
          <description>Adverse Events defined as: oxygen saturation &lt; 92%; respiratory rate &lt;10 breaths/min; systolic blood pressure &lt; 90 mm Hg)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 or more adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Supplementary Analgesia</title>
        <description>count of participants who needed or did not needed additional analgesia</description>
        <time_frame>2 hours post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCA 1 mg Demand Dose</title>
            <description>0.1 mg/kg morphine loading dose followed by PCA with 1.0 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
          </group>
          <group group_id="O2">
            <title>PCA 1.5 mg Demand Dose</title>
            <description>0.1 mg/kg morphine loading dose followed by PCA with 1.5 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
          </group>
          <group group_id="O3">
            <title>Non-PCA Comparison Group</title>
            <description>0.1 mg/kg morphine loading dose followed by additional analgesia supplemented as needed at the discretion of the treating physician, using usual procedures for monitoring and treating pain.
morphine: Intravenous morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Supplementary Analgesia</title>
          <description>count of participants who needed or did not needed additional analgesia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Needed supplementary medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not need supplementary medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 8 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PCA 1 mg Demand Dose</title>
          <description>0.1 mg/kg morphine loading dose followed by PCA with 1.0 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
        </group>
        <group group_id="E2">
          <title>PCA 1.5 mg Demand Dose</title>
          <description>0.1 mg/kg morphine loading dose followed by PCA with 1.5 mg morphine demand dosing every 6 minutes
Patient-controlled analgesia: Intravenous morphine delivered via Curlin painsmart PCA device
morphine: Intravenous morphine</description>
        </group>
        <group group_id="E3">
          <title>Non-PCA Comparison Group</title>
          <description>0.1 mg/kg morphine loading dose followed by additional analgesia supplemented as needed at the discretion of the treating physician, using usual procedures for monitoring and treating pain.
morphine: Intravenous morphine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Transient decrease in blood pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Oxygen Desaturation as measured by pulse oximetry</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation</sub_title>
                <description>Transient sluggish response to loud sound after also receiving lorazepam (non-study drug)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Polly Bijur, PhD</name_or_title>
      <organization>Albert Einstein College of Medicine</organization>
      <phone>718-430-4217</phone>
      <email>polly.bijur@einstein.yu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

